RxDoctor Payments DataLook up a doctor →

April Egbert, APRN

Family · Mount Orab, OHNPI 1780131052

Payments from drug & device makers

$78,493in general payments, 2019–2025

Across 732 payments — averaging $107.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$66K
  • Abbott$5K
  • Boston Scientific$2K
  • AbbVie$1K
  • Vertos Medical, Inc.$749
  • Collegium Pharmaceutical, Inc.$695
  • plus $3K from 26 others
$280in research payments, 2019–2025

Across 1 payment — averaging $280.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$280

What the payments were for

  • Speaking & faculty fees$39,64351%
  • Travel & lodging$20,80427%
  • Food & beverage$18,04623%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$78,493 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$125,190
Medicare patients
204
Services billed
1,498

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen1,413$42,117
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen931$19,429
OxycontinOxycodone Hcl33$13,778
Pregabalin299$12,522
Gabapentin956$12,482
Buprenorphine58$11,654
BelbucaBuprenorphine Hcl21$11,560
LinzessLinaclotide21$11,144
Oxycodone Hcl345$7,652
MovantikNaloxegol Oxalate13$6,897
Tizanidine Hcl341$6,753
Lidocaine61$5,353
Baclofen175$3,421
Naloxone Hcl47$2,616
Fentanyl24$2,564

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$695$13,95133 claims
Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate$31$12,00478 claims
AbbVieLinzess$1,122$11,14421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.

Other family in Mount Orab

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →